全文获取类型
收费全文 | 21782篇 |
免费 | 1731篇 |
国内免费 | 556篇 |
专业分类
耳鼻咽喉 | 51篇 |
儿科学 | 3007篇 |
妇产科学 | 108篇 |
基础医学 | 1836篇 |
口腔科学 | 72篇 |
临床医学 | 2615篇 |
内科学 | 3835篇 |
皮肤病学 | 190篇 |
神经病学 | 947篇 |
特种医学 | 259篇 |
外国民族医学 | 5篇 |
外科学 | 398篇 |
综合类 | 2976篇 |
现状与发展 | 10篇 |
预防医学 | 958篇 |
眼科学 | 105篇 |
药学 | 1412篇 |
7篇 | |
中国医学 | 328篇 |
肿瘤学 | 4950篇 |
出版年
2023年 | 312篇 |
2022年 | 372篇 |
2021年 | 709篇 |
2020年 | 728篇 |
2019年 | 725篇 |
2018年 | 680篇 |
2017年 | 736篇 |
2016年 | 700篇 |
2015年 | 833篇 |
2014年 | 1347篇 |
2013年 | 1514篇 |
2012年 | 1045篇 |
2011年 | 1307篇 |
2010年 | 925篇 |
2009年 | 976篇 |
2008年 | 981篇 |
2007年 | 930篇 |
2006年 | 851篇 |
2005年 | 773篇 |
2004年 | 771篇 |
2003年 | 574篇 |
2002年 | 514篇 |
2001年 | 518篇 |
2000年 | 397篇 |
1999年 | 364篇 |
1998年 | 331篇 |
1997年 | 240篇 |
1996年 | 304篇 |
1995年 | 361篇 |
1994年 | 340篇 |
1993年 | 293篇 |
1992年 | 292篇 |
1991年 | 248篇 |
1990年 | 206篇 |
1989年 | 208篇 |
1988年 | 204篇 |
1987年 | 151篇 |
1986年 | 134篇 |
1985年 | 232篇 |
1984年 | 184篇 |
1983年 | 114篇 |
1982年 | 140篇 |
1981年 | 111篇 |
1980年 | 86篇 |
1979年 | 96篇 |
1978年 | 68篇 |
1977年 | 53篇 |
1976年 | 46篇 |
1975年 | 16篇 |
1974年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Elifcan Aladag Salih Aksu Ibrahim C. Haznedaroglu Nilgun Sayınalp Osman Ozcebe Umit Yavuz Malkan Hakan Goker 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):177-182
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献82.
目的探讨双吲哚马来酰亚胺衍生物L6诱导白血病细胞的凋亡作用及其分子机制。方法采用MTT比色法检测L6对白血病细胞HEL、K562、KG1a的杀伤作用。流式细胞术检测L6对HEL细胞凋亡、周期和分化的影响。Western blotting法检测细胞凋亡相关蛋白的表达。通过体内实验研究L6治疗小鼠白血病的作用效果。结果 MTT比色法结果显示L6对HEL、K562、KG1a细胞具有比阳性对照米哚妥林(PKC412)更显著的抑制活性,半数抑制浓度(IC50)分别为(0.05±0.03)、(0.32±0.01)、(0.19±0.10)μmol/L。L6可以诱导HEL细胞发生凋亡和G2/M期阻滞,诱导HEL细胞向巨核细胞方向分化,且呈剂量效应。Western blotting检测结果表明L6主要通过激活Caspase-3执行细胞凋亡。小鼠肝组织苏木精-伊红(HE)染色显示肝组织内HEL细胞浸润有所减轻,但L6组减轻的效果更明显,表明其可延缓白血病细胞的转移,且效果优于米哚妥林。结论双吲哚马来酰亚胺衍生物L6有较强的抗白血病活性,为新型白血病药物的研发提供参考。 相似文献
83.
84.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
85.
The US Food and Drug Administration granted acalabrutinib approval as the second Bruton tyrosine kinase (BTK) inhibitor to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma as monotherapy or in combination with obinutuzumab. This approval was based on 2 phase 3 trials: ELEVATE-TN and ASCEND. There are several concerns with the design of these trials, including suboptimal treatment of patients in the control arm, expansion of the trial population, and lack of data regarding efficacy or tolerability compared with ibrutinib, a first-in-class drug. The Food and Drug Administration approval of acalabrutinib for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma represents concerning drug approval patterns in the United States and a weakness in evidence generation. 相似文献
86.
87.
Bo Cai Qiyun Sun Jianhui Qiao Changlin Yu Kaixun Hu Tieqiang Liu Bingxia Li Yajing Huang Yi Wang Hongli Zuo Zheng Dong Yaqing Lei Zhiqing Liu Bo Yao Caixia Li Huisheng Ai Mei Guo 《American journal of cancer research》2020,10(11):3852
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have poor prognosis, and the efficacy of chemotherapy plus tyrosine kinase inhibitors (TKIs) followed by mismatched donor stem cell infusion (microtransplantation, MST) has not been determined. We retrospectively summarized 45 patients including 11 undergoing MST with TKIs, 17 receiving allogeneic transplant and 17 undergoing chemotherapy with TKIs. Improved 4-year overall survival rate was observed in the MST group (91%) compared with either transplant group (31%, P = .005) or chemotherapy group (36%, P = .013). The MST group also had higher 2-year and 4-year leukemia-free survival rates (91% and 72%, respectively) compared with either transplant group (33%, P = .005 and 33%, P = .021, respectively) or chemotherapy group (41%, P = .017 and 31%, P = .023, respectively). 2-year and 4-year cumulative incidences of hematologic relapse were lower in the MST group (9% and 28%, respectively) compared with those in the chemotherapy group (56%, P = .025 and 67%, P = .034, respectively). In patients undergoing MST, donor microchimerism was detected (1.07 × 10-5 to 6.6 × 10-4 copies from 9 to 1499 days) in 7 patients, and donor/patient-derived HLA*0201/2402+WT1+CD8+ T cells were found from 0.05% to 0.67% in 6 patients. MST may provide a favorable treatment for patients with Ph+ ALL. 相似文献
88.
89.
《Actas dermo-sifiliográficas》2022,113(4):T401-T406
Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. The mean age of this group when they started treatment upon registration on Biobadaderm was 16.1 years and the mean Psoriasis Area and Severity Index was 9.4. In 67% the first treatment recorded was with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs. 相似文献
90.
Saman K. Hashmi Shoba A. Navai Tiffany M. Chambers Michael E. Scheurer M. John Hicks Rachel E. Rau Maria M. Gramatges 《Pediatric blood & cancer》2020,67(2)
Conjugated hyperbilirubinemia (CHB) and liver transaminase elevation are known complications of acute lymphoblastic leukemia (ALL) therapy, but host risk factors are poorly understood. Among 373 children diagnosed with ALL between 2011 and 2016, clinically significant CHB and transaminase elevation were observed in 15 (4.0%) and 12 (3.2%) children, respectively, during induction and consolidation. Body mass index ≥95th percentile (odds ratio 9.20, 95% confidence interval 2.56–32.96) was the only host factor independently associated with CHB, and no host factors were associated with transaminase elevation. Obese patients warrant closer monitoring of hepatic function to facilitate early intervention prior to the development of severe, adverse hepatic events. 相似文献